journal article·2019-12-04Open access

Combined vaccines for prophylaxis of infectious conditions

Pravin Shende, Mansi Waghchaure

Abstract

In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine products have been developed, like the combined vaccines, or are under development, such as nucleic acid vaccines (DNA and RNA), polymer-based vaccines, etc. Moreover, the possible use of traditional, like aluminium hydroxide and aluminium phosphate, or innovative adjuvants, like monophosphoryl lipid A, polysaccharides and nanoparticulate system, may further increase vaccine effectiveness. This review article focuses on the combined vaccines, which, especially when they are associated with adjuvants, reduce the dosing frequency, and prolong the duration of action, thus providing better vaccine coverage. Marketed preparations, like Typhim Vi, Peda typh and Boostrix showed better vaccine coverage for diseases like typhoid, tetanus, diphtheria and acellular pertussis. The future aspect for the development of combined vaccines will protect not only against infectious diseases but likely even against various infectious conditions, like pneumonia, meningococcal infection and respiratory syncytial virus infection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Viral gastroenteritis research and epidemiology · Hepatitis B Virus Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS

References (51)

Show source-provided references
1. Vaccines [Internet]. World Health Organization; 2018; [cited 2018 Oct 15]. Available from: http://www.who.int/topics/vaccines/en/
2. 10.4103/0974-777X.7729810.4103/0974-777X.77298 ↗
3. 10.1016/j.tmaid.2010.02.00710.1016/j.tmaid.2010.02.007 ↗
4. 10.7774/cevr.2017.6.1.2210.7774/cevr.2017.6.1.22 ↗
5. Vaccine Position Papers [Internet]. World Health Organization; 2018; [cited 2018 Oct 15]. Available from: http://www.who.int/immunization/documents/positionpapers/en/.Sanofi. Pasteur Inc. Diphtheria and tetanus toxoids and acellular pertussis adsorbed inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine (Pentacel): US product information. Available from: http://www.fda.gov/cber/label/pentacelLB.pdf
6. 10.1155/2007/28984210.1155/2007/289842 ↗
7. 10.2165/0148581-200810060-0000810.2165/0148581-200810060-00008 ↗
8. 10.1007/s40272-013-0007-710.1007/s40272-013-0007-7 ↗
9. 10.1080/21645515.2017.130262910.1080/21645515.2017.1302629 ↗
10. 10.1097/MD.000000000000172110.1097/MD.0000000000001721 ↗
11. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–12.
12. 10.1038/nm121610.1038/nm1216 ↗
13. 10.1385/1-59259-399-2:15310.1385/1-59259-399-2:153 ↗
14. 10.1016/j.clim.2018.07.01010.1016/j.clim.2018.07.010 ↗
15. 10.1016/j.vaccine.2004.10.02110.1016/j.vaccine.2004.10.021 ↗
16. 10.1111/cei.1320210.1111/cei.13202 ↗
17. 10.1016/j.vaccine.2003.08.04010.1016/j.vaccine.2003.08.040 ↗
18. Immunology and Vaccine-Preventable Diseases – Pink Book; [Internet]. Cdc.gov.; 2018; [cited 2018 Oct 15]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf
19. 10.2174/156800501460596410.2174/1568005014605964 ↗
20. 10.1016/j.vaccine.2005.07.11110.1016/j.vaccine.2005.07.111 ↗
21. 10.1016/j.provac.2010.03.01410.1016/j.provac.2010.03.014 ↗
22. 10.1128/iai.62.10.4440-4444.199410.1128/iai.62.10.4440-4444.1994 ↗
23. 10.1155/2013/49034610.1155/2013/490346 ↗
24. 10.1016/j.rmed.2011.07.00810.1016/j.rmed.2011.07.008 ↗
25. Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21:27–35.
26. Pietersz GA Esparon SE Proudfoot O inventors. MacFarlane Burnet Centre for Medical Res Ltd-Fairfield Hospital assignee. Flu vaccine admixture of mannan and flu antigen. United States patent US 8 182 821. 2012 May 22.
27. 10.1016/S0264-410X(01)00456-X10.1016/S0264-410X(01)00456-X ↗
28. 10.1038/nm.340910.1038/nm.3409 ↗
29. Hogen Esch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2013;3:406.
30. 10.1016/j.vaccine.2015.08.07610.1016/j.vaccine.2015.08.076 ↗
31. 10.1016/j.coi.2010.04.00410.1016/j.coi.2010.04.004 ↗
32. 10.1111/cei.1229210.1111/cei.12292 ↗
33. 10.1016/j.vaccine.2009.02.00410.1016/j.vaccine.2009.02.004 ↗
34. 10.1080/21691401.2018.151394110.1080/21691401.2018.1513941 ↗
35. 10.1586/erv.09.12310.1586/erv.09.123 ↗
36. 10.1517/14712598.8.2.23510.1517/14712598.8.2.235 ↗
37. 10.1111/jfd.1203210.1111/jfd.12032 ↗
38. 10.3390/polym1001003110.3390/polym10010031 ↗
39. 10.1038/nrd163210.1038/nrd1632 ↗
40. 10.1038/252252a010.1038/252252a0 ↗
41. 10.1016/j.vaccine.2011.04.08110.1016/j.vaccine.2011.04.081 ↗
42. 10.1166/jbn.2013.149110.1166/jbn.2013.1491 ↗
43. 10.1016/j.exppara.2012.09.00110.1016/j.exppara.2012.09.001 ↗
44. 10.1016/j.jconrel.2012.08.01610.1016/j.jconrel.2012.08.016 ↗
45. 10.1016/j.jconrel.2012.03.01610.1016/j.jconrel.2012.03.016 ↗
46. 10.2174/15672010577437030210.2174/156720105774370302 ↗
47. 10.1016/j.vaccine.2009.05.02910.1016/j.vaccine.2009.05.029 ↗
48. 10.1177/205101361454144010.1177/2051013614541440 ↗
49. Brito LA, Kommareddy S, Maione D, et al. Self-amplifying mRNA vaccines. In: Advances in genetics, vol. 89. Massachusetts: Academic Press; 2015. p. 179–233.
50. 10.1080/1061186X.2018.147651810.1080/1061186X.2018.1476518 ↗
51. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗